人福医药：控股子公司屈螺酮炔雌醇片获得药品注册证书

Group 1 - The core point of the article is that the company, Renfu Pharmaceutical, has received a drug registration certificate for its contraceptive product, Cyproterone Acetate and Ethinylestradiol Tablets, from the National Medical Products Administration [1] - The product is intended for female contraception and will be managed as a Class A over-the-counter drug after approval [1] - The company invested approximately 8.5 million yuan in the research and development of this product, which was submitted for approval in March 2024 [1] Group 2 - The estimated national sales for Cyproterone Acetate and Ethinylestradiol Tablets in 2024 is around 320 million yuan [1] - The approval signifies that the company is now qualified to sell this product in the domestic market, thereby enriching its product line [1] - Future sales performance may be influenced by industry policies and market conditions [1]